Aurobindo and Intas submit binding offers to buyout Teva UK
Advertisement
Advertisement
Aurobindo and Intas, the drug makers from India, are among the final contenders in the list of buyers for the UK and Irish business of Israeli generics maker Teva. Both Indian companies have submitted binding offers of about $1 billion along with firm financing commitments, multiple sources aware of the matter told ET.
Teva is selling its assets after it acquired Allergan Plc's generics business for $40.5-billion in July last year. Prior to that, around 80 of its products in the US were sold to drug makers like Dr. Reddy's, Sagent, Cipla, Zydus Cadila, Aurobindo and Perrigo.
Aurobindo and Intas are in competition with London-based PE firm
It could still take some weeks for the buyer to get finalised, and preference would be given to someone with prior experience in the European generics market.
Advertisement
For
Image source
Advertisement
- Colon cancer rates are rising in young people. If you have two symptoms you should get a colonoscopy, a GI oncologist says.
- I spent $2,000 for 7 nights in a 179-square-foot room on one of the world's largest cruise ships. Take a look inside my cabin.
- An Ambani disruption in OTT: At just ₹1 per day, you can now enjoy ad-free content on JioCinema
- In second consecutive week of decline, forex kitty drops $2.28 bn to $640.33 bn
- SBI Life Q4 profit rises 4% to ₹811 crore
- IMD predicts severe heatwave conditions over East, South Peninsular India for next five days
- COVID lockdown-related school disruptions will continue to worsen students’ exam results into the 2030s: study
- India legend Yuvraj Singh named ICC Men's T20 World Cup 2024 ambassador
- JNK India IPO allotment date
- JioCinema New Plans
- Realme Narzo 70 Launched
- Apple Let Loose event
- Elon Musk Apology
- RIL cash flows
- Charlie Munger
- Feedbank IPO allotment
- Tata IPO allotment
- Most generous retirement plans
- Broadcom lays off
- Cibil Score vs Cibil Report
- Birla and Bajaj in top Richest
- Nestle Sept 2023 report
- India Equity Market